secwatch.observer — SEC 8-K summary
======================================

Issuer:     Stoke Therapeutics, Inc. (STOK)
CIK:        0001623526
Form:       8-K
Filed at:   2025-10-06T23:59:59+00:00
Accession:  0001193125-25-230925
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stoke Therapeutics appoints Ian F. Smith as permanent CEO; interim role since March 2025
--------------------------------------------------------------------------------

- Ian F. Smith, 59, appointed CEO effective Oct 6, 2025; served as interim CEO since March 19, 2025.
- Annual base salary of $715,000; eligible for annual bonus target of 65% of base salary (no 2025 bonus).
- Receives $500,000 sign-on bonus (repayable if resigns within 12 months) and $500,000 performance bonus based on metrics.
- Equity grant: option for 570,000 shares (4-yr vest) and RSU for 380,000 shares (4-yr annual vest).
- Dr. Tzianabos resigns as Interim Executive Chair, resumes as independent director and Chair of the Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1623526/000119312525230925/0001193125-25-230925-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1623526/000119312525230925/d55930d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-230925

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer